The agreements with ViiV Healthcare do not impact Bristol-Myers Squibb’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla

Little effect has been seen in the treatment of SUI, while more promising data is present for the treatment of recurrent UTI, vaginal atrophy, dyspareunia, and possibly OAB symptoms